Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNβ-NIS) Monotherapy and in Combination With Avelumab in Patients With Refractory Solid Tumors

Trial Profile

Phase 1/2 Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNβ-NIS) Monotherapy and in Combination With Avelumab in Patients With Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Avelumab (Primary) ; VSV-IFNbeta-NIS (Primary)
  • Indications Colorectal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Vyriad
  • Most Recent Events

    • 07 Feb 2019 Planned End Date changed from 1 Jul 2019 to 1 Feb 2020.
    • 07 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Sep 2019.
    • 24 Jul 2018 Single group assignment has been changed to parallel. Treatment arms has been changed from 1 to 2, number of planned patient number has been increased.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top